Source:http://linkedlifedata.com/resource/pubmed/id/21123968
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
2010-12-2
|
| pubmed:abstractText |
Splenic marginal zone lymphoma (SP-MZL) is a rare low-grade B-cell neoplasm that often shows leukemic manifestation. Less than 20% of cases of SP-MZL express CD5. We analyzed 11 cases of CD5-positive SP-MZL with leukemic manifestation. The clinical characteristics of these cases did not differ from those of CD5-negative SP-MZL. Flow cytometry revealed positive results as follows : CD3, 0/9 ; CD5, 11/11 ; CD10, 0/11 ; CD11c, 4/10, CD13, 5/11 ; CD19, 11/11 ; CD20, 10/11 ; CD21, 4/4 ; CD22, 7/7 ; CD23, 5/10 ; CD25, 8/11 ; FMC7, 5/7 ; ? type 6/9, and ? type 2/9. All 3 cases with monoclonal ?-globulinemia expressed CD13. Resected spleen exhibited a proliferation of neoplastic cells in white pulp in all 8 splenectomy patients and a marginal pattern was detected in 5 patients. Only 2 cases showed involvement of red pulp. Immunohistochemistry showed that the lymphoma cells were positive for CD5, CD20, and BCL-2 and negative for CD3, CD10, cyclin D1, BCL-6, and MUM-1 in all 11 cases. These results suggest that CD5-positive SP-MZL differs from B-cell chronic lymphocytic leukemia, that CD13 expression is found in about half of CD5-positive SP-MZL cases, and that CD5-positive SP-MZL may be related to memory B-cell neoplasm or plasma cell differentiation.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1880-9952
|
| pubmed:author |
pubmed-author:AndoKiyoshiK,
pubmed-author:KikuchiTomokiT,
pubmed-author:KoikeTadashiT,
pubmed-author:KojimaMinoruM,
pubmed-author:MarutsukaKousukeK,
pubmed-author:MatsumotoToshiharuT,
pubmed-author:MoriuchiMakikoM,
pubmed-author:MuraseTakuheiT,
pubmed-author:NakamuraNaoyaN,
pubmed-author:OgiyaDaisukeD,
pubmed-author:OshimiKazuoK,
pubmed-author:SatoErikoE,
pubmed-author:TokunakaMamiM,
pubmed-author:TsunodaSinichirouS,
pubmed-author:Yara KikutiYukieY
|
| pubmed:issnType |
Electronic
|
| pubmed:volume |
50
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
107-12
|
| pubmed:meshHeading |
pubmed-meshheading:21123968-Adult,
pubmed-meshheading:21123968-Aged,
pubmed-meshheading:21123968-Aged, 80 and over,
pubmed-meshheading:21123968-Antigens, CD5,
pubmed-meshheading:21123968-Female,
pubmed-meshheading:21123968-Flow Cytometry,
pubmed-meshheading:21123968-Humans,
pubmed-meshheading:21123968-Immunohistochemistry,
pubmed-meshheading:21123968-Immunophenotyping,
pubmed-meshheading:21123968-Lymphoma, B-Cell, Marginal Zone,
pubmed-meshheading:21123968-Male,
pubmed-meshheading:21123968-Middle Aged,
pubmed-meshheading:21123968-Splenic Neoplasms,
pubmed-meshheading:21123968-Tumor Markers, Biological
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Characteristics of CD5-positive splenic marginal zone lymphoma with leukemic manifestation ; clinical, flow cytometry, and histopathological findings of 11 cases.
|
| pubmed:affiliation |
Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan. 6 amud 010@is.icc.u-tokai.ac.jp
|
| pubmed:publicationType |
Journal Article
|